SCHEMBL17817682

SCHEMBL17817682

Cc1nc(-c2ccccc2)c2c(=O)[nH]c3ccccc3n12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.56
PDE6D O43924 1/20 0.56
PDE8A O60658 1/20 0.56
PDE5A O76074 1/20 0.56
PDE9A O76083 1/20 0.56
PDE8B O95263 1/20 0.56
PDE6A P16499 1/20 0.56
PDE6G P18545 1/20 0.56
PDE4A P27815 1/20 0.56
PDE6B P35913 1/20 0.56
PDE6C P51160 1/20 0.56
PDE1A P54750 1/20 0.56
PDE1B Q01064 1/20 0.56
PDE4B Q07343 1/20 0.56
PDE4C Q08493 1/20 0.56
PDE4D Q08499 1/20 0.56
PDE3B Q13370 1/20 0.56
PDE7A Q13946 1/20 0.56
PDE6H Q13956 1/20 0.56
PDE1C Q14123 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30728010 0.85 PDE2A (0.70) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL175950 0.72 PDE2A (1.00) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL20893121 0.71 ADORA2A (0.47) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL22045209 0.70 KDM4E (0.52) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL29379322 0.69 PDE10A (0.74) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL14361375 0.69 POLB (0.68) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL17817683 0.69 KDM4E (0.59) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL9052411 0.68 POLB (0.55) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL972909 0.68 ADORA3 (0.53) PDE2APDE6DPDE8APDE5APDE9A
SCHEMBL23295676 0.68 KDM4E (0.54) PDE2APDE6DPDE8APDE5APDE9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016094226-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GLYCOREGIMMUNE, INC. (US) 2016-06-16 WO disclosed
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS ALTIUM GROWTH FUND, LP 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS RXRA, RXRG, CX3CR1 PDE2A 1728/4885PDE6D 2332/4885PDE8A 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.